Study to Compare Exposure of TA Following Administration of Either FX006 or TAcs in Patients With Bilateral Knee OA

Exclusion Criteria

• •Reactive arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or arthritis associated with inflammatory bowel disease
• •History of infection in either knee joint
• •Clinical signs and symptoms of active knee infection or crystal disease in either knee within 1 month of Screening
• •Unstable joint (such as a torn anterior cruciate ligament) in either knee within 12 months of Screening
• •Presence of surgical hardware or other foreign body in either knee
• •Surgery or arthroscopy of either knee within 12 months of Screening
• •IA treatment of any joint with any of the following agents within six (6) months of Screening: any corticosteroid preparation (investigational or marketed, including FX006), any biologic agent (e.g., platelet rich plasma (PRP) injection, stem cells, prolotherapy, amniotic fluid injection; investigational or marketed).
• •IA treatment in either knee with hyaluronic acid (investigational or marketed) within 6 months of Screening
• •Parenteral or oral corticosteroids (investigational or marketed) within 3 months of Screening
• •Inhaled, intranasal or topical corticosteroids (investigational or marketed) within 2 weeks of Screening
• •Females who are pregnant or nursing or plan to become pregnant during the study; men who plan to conceive during the study